ClinicalTrials.gg
Not yet recruitingNCT07422948Updated Feb 20, 2026

Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.

An interventional study of Midodrine and Standard Medical Treatment in Acute on Chronic Liver Failure, sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India — 17 open to participants now, 17 under way, 2 of them phase 3. Acute-On-Chronic Liver Failure · Institute of Liver and Biliary Sciences, India.

Planned enrollment
11th of 28
113 · median 95
Started
2026
with 3 others
No phase
23 of 39
8 open now
Primary completion
2027-08
later than 12 of 16 live
Registered
39th of 39
by date

Among the 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India, this one is the 11th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 39th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

17 of the 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India, or all of them as a file.
02

Study summary

Ascites is a cardinal and debilitating complication in patients with acute-on-chronic liver failure (ACLF), significantly correlating with disease severity and poor prognosis. The underlying pathophysiology is driven by severe splanchnic arterial vasodilation, which reduces effective arterial blood volume and triggers compensatory neurohumoral activation. This cascade leads to profound sodium retention, renal vasoconstriction, and circulatory instability. Consequently, patients with ACLF frequently experience diuretic intolerance and are at elevated risk for severe complications, including electrolyte disturbances, acute kidney injury (AKI), and hepatorenal syndrome (HRS).

Current management strategies rely heavily on diuretics and albumin; however, the efficacy of diuretics is often limited by systemic hypotension and pre-existing renal impairment, leading to frequent treatment failure or diuretic-induced complications. Existing clinical guidelines lack definitive recommendations regarding the preemptive use of vasoconstrictors to stabilize hemodynamics before ascites becomes refractory. Midodrine, an oral alpha-1 adrenergic agonist, targets this circulatory dysfunction by increasing systemic vascular resistance and improving renal perfusion. This randomized controlled trial aims to evaluate the efficacy and safety of the early initiation of midodrine in achieving better control of ascites and preventing the progression to renal complications in patients with acute-on-chronic liver failure.

03

Conditions studied

  • Acute on Chronic Liver Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. ACLF
  3. Ascites (Grade II/III).
  4. Willing/able for salt restriction, labs, urine collections, and follow-ups; consent obtained.

Exclusion criteria

Exclusion Criteria:

  1. SCr ≥ 1.5 mg/dL OR ongoing AKI >stage I
  2. Persistent or uncorrectable severe hyponatremia (Na ≤120 mEq/L), hyperkalemia (>6.0 mEq/L) or any other critical electrolyte imbalance.
  3. ascites
  4. Spontaneous bacterial peritonitis
  5. Hepatic encephalopathy grade II-III.
  6. Shock, need for IV vasopressors, SBP \<90 mmHg or MAP \<65 despite fluids/albumin.
  7. Active GI bleed, uncontrolled infection/sepsis, or SBP at screening.
  8. Severe cardiomyopathy, critical valvular disease, arrhythmias contraindicating α-agonists.
  9. ACLF patients on Mechanical ventilation/ICU/ionotropes/High flow oxygen
  10. Pregnancy, lactation.
  11. /intolerance to midodrine.
  12. Significant LUTS.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (estimated)

Study arms

  • Experimental
    Midodrine+SMT

    1. Sodium restriction to ≤5 g/day. 2. Combination of spironolactone 50 mg + furosemide 20 mg daily as a fixed dose. a) Stepwise titration every 3 days if tolerated, with careful monitoring for AKI, hyponatremia, encephalopathy. Dose reduction or discontinuation if diuretic-related complications develop. 3. Other supportive measures: as per the clinician 1. Lactulose ± rifaximin for hepatic encephalopathy prophylaxis/management. 2. IV albumin during LVP 3. Antibiotic prophylaxis/treatment as indicated for SBP or systemic infections. 4. Correction of electrolytes and renal support as needed. 5. Management of precipitating factors (alcohol, infection, flare of hepatitis, GI bleed, etc.). 4. Midodrine: Start with 5 mg TDS. Increase 2.5 mg every day with target MAP increase of 10 mmHg, maximum upto 15 mg TDS.

    Drug: Midodrine · Other: Standard Medical Treatment

  • Active comparator
    Placebo+SMT

    1. Sodium restriction to ≤5 g/day. 2. Combination of spironolactone 50 mg + furosemide 20 mg daily as a fixed dose. a) Stepwise titration every 3 days if tolerated, with careful monitoring for AKI, hyponatremia, encephalopathy. Dose reduction or discontinuation if diuretic-related complications develop. 3. Other supportive measures: as per the clinician 1. Lactulose ± rifaximin for hepatic encephalopathy prophylaxis/management. 2. IV albumin during LVP 3. Antibiotic prophylaxis/treatment as indicated for SBP or systemic infections. 4. Correction of electrolytes and renal support as needed. 5. Management of precipitating factors (alcohol, infection, flare of hepatitis, GI bleed, etc.). 4. Placebo

    Other: Standard Medical Treatment

Interventions

  • Start with 5 mg TDS. Increase 2.5 mg every day with target MAP increase of 10 mmHg, maximum upto 15 mg TDS.

  • OtherStandard Medical Treatment

    1. Sodium restriction to ≤5 g/day. 2. Combination of spironolactone 50 mg + furosemide 20 mg daily as a fixed dose. a) Stepwise titration every 3 days if tolerated, with careful monitoring for AKI, hyponatremia, encephalopathy. Dose reduction or discontinuation if diuretic-related complications develop. 3. Other supportive measures: as per the clinician 1. Lactulose ± rifaximin for hepatic encephalopathy prophylaxis/management. 2. IV albumin during LVP 3. Antibiotic prophylaxis/treatment as indicated for SBP or systemic infections. 4. Correction of electrolytes and renal support as needed. 5. Management of precipitating factors (alcohol, infection, flare of hepatitis, GI bleed, etc.).

06

What researchers measure

Primary outcomes

  1. Proportion of patients with no ascites between the two groups at day 28.

    Time frame: Day 28

Secondary outcomes

  1. Percentage of patients with no ascites

    Time frame: Day 7 & 14

  2. Partial ascites response

    Time frame: 7,14,28 days

  3. Absent response or worsening of ascites

    Time frame: 28 day

  4. Large Volume Paracentesis requirement in two groups

    Time frame: day 7 and 28

  5. Cumulative dose of diuretics/Albumin/midodrine/carvedilol

    Time frame: day 28

  6. Change in Intra Abdominal pressure measured by manometer between both groups

    Time frame: Day 7

  7. Change in MAP between both groups.

    Time frame: 7 days, then day 14 and 28

  8. Change in Weight change between both groups.

    Time frame: 7 days, then day 14 and 28

  9. Change in urine output daily between both groups

    Time frame: 7 days, then day 14 and 28

  10. Change in HR between both groups

    Time frame: 7 days, then day 14 and 28

  11. Change in urine Na

    Time frame: day 3, 7 and 28 from baseline

  12. Change in MELD score between both groups.

    Time frame: day 4, 7 and 28

  13. Change in AARC score between both groups.

    Time frame: day 4, 7 and 28

  14. Reduction in Hepatic Venous Pressure Gradient between both groups.

    Time frame: 14 and 28 days.

  15. Mortality

    Time frame: day 28

  16. New onset AKI between both groups.

    Time frame: day 28

  17. New onset SBP between both groups

    Time frame: day 28

  18. New onset AKI, SBP, HE, Hyponatremia, shock and need for MV

    Time frame: day 28

  19. New onset HE between both groups

    Time frame: day 28

  20. New onset Hyponatremia between both groups.

    Time frame: day 28

  21. New onset shock between both groups.

    Time frame: day 28

  22. New onset need for MV between both groups

    Time frame: day 28

  23. Treatment related adverse effects

    Time frame: day 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.

Of 32 interventional studies with no phase under Acute-On-Chronic Liver Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 20, 2026
StartEst.
Feb 5, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422948
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 5, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Dr Chunnee Zangmu Bhutia, MD
Contact
czb.cr7@gmail.com
01146300000
Dr Ankur S Jindal, DM
Contact
ankur.jindal3@gmail.com
01146300000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midodrine

Start the discussion